EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SGLT2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis (EDKA) in Hematologic Malignancy Patients: A Case Series

Andrew Artz, Tiffany Nguyen iD, Raynald Samoa, Hoim Kim, Wyndie Tse, Rami Jin, Svetlana Goutnik

Advances in Hematology · 2025-01 · 2025 (1)

DOI: 10.1155/ah/7244013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Hematology, online erschienen am 08.10.2025. Verfasst von Andrew Artz und 6 weiteren Autor:innen. Beteiligte Einrichtung: City of Hope, Duarte, California, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium‐glucose Cotransporter 2 inhibitors (SGLT2i) are widely used and effective pharmacotherapeutic options that are first‐line therapy for Type 2 diabetes mellitus (T2DM) and congestive heart failure. A major adverse effect of SGLT2i usage is diabetic ketoacidosis (DKA). SGLT2i‐induced DKA commonly presents as euglycemic DKA (EDKA). The safety of empagliflozin in cancer patients is not well established. High intensity treatment of hematologic malignancy poses a unique set of risk factors for EDKA. Four cases of empagliflozin‐associated EDKA in hematologic malignancy patients were identified through pharmacy adverse event reporting at a cancer research hospital. All patients were euglycemic except one patient who required CRS/ICANS treatment with dexamethasone, causing steroid‐induced hyperglycemia. All four patients had weight loss due to reasons including, but not limited to, reduced oral intake, diarrhea, nausea, and pain. Infections and/or neutropenic fever were also commonalities throughout the four patients. In all patients, DKA contributed to iatrogenic ICU admissions and prolonged hospital stays. SGLT2i use in hematologic malignancy patients may increase the risk of DKA due to high risk of anorexia, weight loss, and infections, all highly associated with intensive treatment that can disrupt the availability and sensitivity to insulin. In patients receiving SGLT2i, clinicians should be aware of risk factors for DKA as well as potential euglycemic presentation to ensure close clinical and laboratory monitoring to facilitate rapid diagnosis and treatment of DKA.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitoreuglycemic DKAhematology

Autor:innen und Institutionen

  • City of Hope, Duarte, California, USA.

ORCID-Profile: Tiffany Nguyen

Zitieren

APA

Artz, A., Nguyen, T., Samoa, R., Kim, H., Tse, W., Jin, R., & Goutnik, S. (2025). SGLT2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis (EDKA) in Hematologic Malignancy Patients: A Case Series. Advances in Hematology, 2025(1). https://doi.org/10.1155/ah/7244013

Vancouver

Artz A, Nguyen T, Samoa R, Kim H, Tse W, Jin R, et al. SGLT2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis (EDKA) in Hematologic Malignancy Patients: A Case Series. Advances in Hematology. 2025;2025(1). doi:10.1155/ah/7244013

BibTeX
@article{Artz2025,
  author = {Artz, Andrew and Nguyen, Tiffany and Samoa, Raynald and Kim, Hoim and Tse, Wyndie and Jin, Rami and Goutnik, Svetlana},
  title = {SGLT2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis (EDKA) in Hematologic Malignancy Patients: A Case Series},
  journal = {Advances in Hematology},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/ah/7244013}
}
Kostenlos starten →